PMID: 9654256Jul 8, 1998Paper

Randomised trial of interferon alpha-2a as adjuvant therapy in resected primary melanoma thicker than 1.5 mm without clinically detectable node metastases. French Cooperative Group on Melanoma

Lancet
J J GrobJ J Bonerandi

Abstract

Owing to the limited efficacy of therapy on melanoma at the stage of distant metastases, a well-tolerated adjuvant therapy is needed for patients with high-risk primary melanoma. Our hypothesis was that an adjuvant treatment with low doses of interferon alpha could be effective in patients with localised melanoma. After resection of a primary cutaneous melanoma thicker than 1.5 mm, patients without clinically detectable node metastases were randomly assigned to receive either 3x10(6) IU interferon alpha-2a, three-times weekly for 18 months, or no treatment. The primary endpoint was the relapse-free interval. 499 patients were enrolled, of whom 489 were eligible. When used as part of a sequential procedure, interferon alpha-2a was of significant benefit for relapse-free interval (p=0.038). A long-term analysis, after a median follow-up of 5 years, showed a significant extension of relapse-free interval (p=0.035) and a clear trend towards an increase in overall survival (p=0.059) in interferon alpha-2a-treated patients compared with controls. There were 100 relapses and 59 deaths among the 244 interferon alpha-2a-treated patients compared with 119 relapses and 76 deaths among the 245 controls. The estimated 3-year-relapse rates w...Continue Reading

References

Jan 1, 1992·International Journal of Radiation Oncology, Biology, Physics·I F Tannock
Jan 15, 1995·Cancer·A Barth, D L Morton

❮ Previous
Next ❯

Citations

Sep 5, 2002·Cancer·Vernon K Sondak
Aug 24, 2006·Der Hautarzt; Zeitschrift für Dermatologie, Venerologie, und verwandte Gebiete·A Hauschild, U R Kleeberg
May 15, 2008·Der Hautarzt; Zeitschrift für Dermatologie, Venerologie, und verwandte Gebiete·A HauschildW Tilgen
Jun 1, 2010·Der Hautarzt; Zeitschrift für Dermatologie, Venerologie, und verwandte Gebiete·K C KählerA Hauschild
Nov 2, 2012·Der Hautarzt; Zeitschrift für Dermatologie, Venerologie, und verwandte Gebiete·B M RudolphS Grabbe
Oct 26, 2012·Der Hautarzt; Zeitschrift für Dermatologie, Venerologie, und verwandte Gebiete·L ZimmerD Schadendorf
Sep 17, 2005·HNO·E S Schultz, G Schuler
Jun 10, 2006·Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft·E RichtigJ Smolle
Jun 12, 2002·Current Treatment Options in Oncology·V K SondakL M Schuchter
Apr 30, 2003·Current Treatment Options in Oncology·Alicia TerandoVernon K Sondak
Dec 21, 2000·Current Oncology Reports·J Stebbing, M Gore
May 4, 2012·Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico·Enrique EspinosaUNKNOWN Grupo Español de Melanoma (GEM)
May 15, 2003·The Surgical Clinics of North America·Charles Komen Brown, John M Kirkwood
Nov 30, 2000·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·J L González-LarribaJ Toribio
Dec 16, 1998·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·J M Kirkwood
Dec 16, 1998·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·A M Eggermont
Oct 30, 2001·Critical Reviews in Oncology/hematology·S Retsas
Oct 26, 2002·Critical Reviews in Oncology/hematology·R Molife, B W Hancock
Jul 11, 2003·Critical Reviews in Oncology/hematology·Filippo de BraudNatale Cascinelli
Mar 14, 2003·Critical Reviews in Oncology/hematology·Timothy M Pawlik, Vernon K Sondak
Apr 27, 2000·Critical Reviews in Oncology/hematology·A J Bremers, G Parmiani
Aug 27, 2005·The Surgeon : Journal of the Royal Colleges of Surgeons of Edinburgh and Ireland·D KavanaghN J O'Higgins
Feb 15, 2000·Clinical and Experimental Dermatology·R Russell-Jones
Oct 24, 2000·Clinical and Experimental Dermatology·S Whittaker
Dec 21, 2000·International Journal of Dermatology·B M Coldiron
Sep 3, 2004·The New England Journal of Medicine·Hensin TsaoArthur J Sober
Jul 2, 2005·Cancer Biotherapy & Radiopharmaceuticals·Michael FluckJens Atzpodien
Mar 2, 2011·Cancer Biotherapy & Radiopharmaceuticals·Robert O Dillman
Jul 28, 2009·Annals of Oncology : Official Journal of the European Society for Medical Oncology·A M M EggermontA Hauschild
Jan 12, 2011·Annals of Oncology : Official Journal of the European Society for Medical Oncology·F EgbertsA Hauschild
Sep 26, 2012·Annals of Oncology : Official Journal of the European Society for Medical Oncology·D SchadendorfL Zimmer
Feb 25, 2010·Journal of the National Cancer Institute·Simone MocellinDonato Nitti
Mar 7, 2002·Current Opinion in Oncology·Alexander M M Eggermont
Jul 11, 2007·The Cancer Journal·Gaurav D Shah, Paul B Chapman
Mar 29, 2012·The Cancer Journal·Diwakar DavarJohn M Kirkwood
Jun 27, 2000·Australian and New Zealand Journal of Medicine·P Hersey
Jan 29, 2011·Dermatologic Surgery : Official Publication for American Society for Dermatologic Surgery [et Al.]·Florent GrangeMarie Francoise Avril

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.